Eli Lilly has linked its amylin agonist eloralintide to up to 20.1% weight loss at Week 48, encouraging the drugmaker to ...

After a company-wide restructuring costing some DKK 9 billion ($1.38 billion), Novo’s path to success lies in its ability to ...

Novo Nordisk (NYSE:NVO) shares have drawn attention recently as investors look for clues about what might be driving the stock's movement this month. In the absence of major headlines, valuation and ...

See why Novo Nordisk A/S stock is primed for a rebound despite recent declines. Click for more about NVO growth catalysts in ...